Compare LRN & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | VERA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2007 | 2021 |
| Metric | LRN | VERA |
|---|---|---|
| Price | $78.79 | $29.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $109.00 | $77.50 |
| AVG Volume (30 Days) | 556.9K | ★ 2.2M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $917,734,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $4.47 | $792.38 |
| P/E Ratio | $10.86 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $23.05 |
| 52 Week High | $155.06 | $56.05 |
| Indicator | LRN | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 36.29 |
| Support Level | $77.37 | N/A |
| Resistance Level | $88.18 | $36.95 |
| Average True Range (ATR) | 2.20 | 2.09 |
| MACD | -0.11 | -0.41 |
| Stochastic Oscillator | 45.26 | 11.38 |
Stride Inc is a technology company providing an educational platform to deliver proprietary and third-party curriculum, software systems, and educational services designed to facilitate individualized learning for students and adults throughout the U.S. The platform delivers products and services to attract, enroll, educate, track progress, and support students. It provides customized solutions to public and private schools, school districts, charter boards, employers, government agencies, and consumers. Its platform addresses two markets in the K-12 space: General Education and Career Learning, with products and services for the General Education market predominantly focused on core subjects for kindergarten through twelfth grade students.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.